BMCS BioTech Medics Inc (PK)

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has engaged the Washington, D.C. law firm of Hogan & Hartson, LLP to advise it, in conjunction with meeting any FDA requirements to market BioTech's multi-patented SHBAN(TM) Antiseptic Hand Sanitizer Solution Products.

BioTech has recently commenced independent clinical testing of SHBAN(TM) Hand Sanitizer Solution to determine if it reduces (or kills) the H1N1 (Swine) Influenza A virus.

In 2007 BioTech conducted an independent study in England to determine the efficacy of SHBAN against Avian H5N1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu). BioTech reported that the SHBAN Solution had clinically proven it had topically reduced (or killed) the Avian Influenza virus.

SHBAN is a bio-degradable product superior to most anti-bacterial hand sanitizers because 1) SHBAN is longer lasting, SHBAN does NOT contain alcohol gel which has poisoned over 22,000 children in the USA after application; 2) SHBAN is non-toxic when used as directed on humans; 3) SHBAN is non-staining; 4) SHBAN is non-flammable; and 5) SHBAN contains no ammonia, bleach, Benzalkonium Chloride (BOC), Triclosan® nor fragrance, or lotion ingredients. Most hand sanitizer products cannot make all of these claims.

SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and a patent pending for the US and international patent. SHBAN is a trademark of BioTech Medics, Inc. BioTech is seeking and negotiating USA and foreign distributorships at this time.

SHBAN(TM) in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Prior research and clinical studies have been conducted at the University of TX Medical Branch, Galveston, TX; Microbiology & Biochemical Assay Laboratories - Houston, Texas; Pathology Associates, Pasadena, Texas; Texas A & M University - College of Veterinary Medicine, College Station, Texas; Baylor College of Dentistry, Dallas, TX; Allergan, Irvine, CA; Culleen Eye Institute, Baylor College of Medicine, Houston, Texas.

Safe Harbor: Forward-Looking Statements

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Tom Wood Sr. V.P. Sales Phone 972-849-3782